Poolbeg Pharma PLC (LON:POLB – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as GBX 9.30 and last traded at GBX 9.04, with a volume of 1485805 shares changing hands. The stock had previously closed at GBX 9.
Analyst Ratings Changes
Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Monday, July 13th.
Read Our Latest Analysis on Poolbeg Pharma
Poolbeg Pharma Price Performance
About Poolbeg Pharma
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
Recommended Stories
- Five stocks we like better than Poolbeg Pharma
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
